HK2 and prostate cancer: However, K315/492R mutation led to increased glucose uptake and lactate production in different prostate cancer cells (Fig. 3a, b and Supplementary Fig. 4a, b), demonstrating that SUMO-defective HK2 enhances glycolytic flux in prostate cancer cells.